The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
Investors flock to cryptocurrencies, seeking a hedge against a weakening U.S. dollar and a prolonged government shutdown.
Weaker-than-expected jobs data has bolstered investor expectations for another Federal Reserve interest rate cut in October, pushing major indices to record closes.
Investment giant advises 'conservative' allocation to digital assets for certain clients, signaling growing mainstream acceptance.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.
Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).
Institutional demand and economic uncertainty fuel the historic rally in the world's largest cryptocurrency, pushing the market into a bullish frenzy.